- Home
- ACNB vs PROK Comparison
ACNB vs PROK Comparison
Compare ACNB & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACNB | PROK |
|---|---|---|
| Founded | 1857 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.6M | 417.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACNB | PROK |
|---|---|---|
| Price | $52.42 | $2.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $49.50 | $6.25 |
| AVG Volume (30 Days) | 24.4K | ★ 1.2M |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $136,676,000.00 | $744,000.00 |
| Revenue This Year | $41.47 | $918.66 |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | $15.46 | ★ N/A |
| Revenue Growth | ★ 28.45 | N/A |
| 52 Week Low | $35.70 | $0.46 |
| 52 Week High | $52.26 | $7.13 |
Technical Indicators
Market Signals| Indicator | ACNB | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 73.71 | 41.86 |
| Support Level | $48.50 | $2.06 |
| Resistance Level | $49.85 | $2.29 |
| Average True Range (ATR) | 1.03 | 0.17 |
| MACD | 0.27 | 0.01 |
| Stochastic Oscillator | 89.05 | 19.67 |
Price Performance
Historical ComparisonAbout ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.